Regenerative medical devices company Tissue Regenix Group posted a first-half loss, as higher revenue was offset by costs.
Pre-tax losses for the six months through June amounted to £4.3m, narrowing from £5.4m of losses on-year.
Sales increased by 61% on a pro-forma basis to £5.6m, while gross margins improved by 12.1 percentage points to 56%.
Costs related to financing, depreciation and share-based payments to executives all rose.
'We have delivered a strong first half performance,' chief executive Steve Couldwell said.
'I am pleased with the growing momentum across our business and we increased market penetration in our key clinical areas as a result of the good progress against our refined strategy.'
At 9:21am: (LON:TRX) Tissue Regenix Group PLC share price was +0.63p at 9.38p